Skip to main content
Equibles
ODTX logo

ODTX · Odyssey Therapeutics, Inc. · Metrics

Track ODTX — free

Use ODTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ODTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$19.23 +0.35 (+1.85%) At close · Nov 6
Russell 2000 member Rebalance outlook locked
Market Cap
$897.43M
Shares
48.07M
Volume · Nov 6 577.26K Avg daily vol (3M) 285.94K

ODTX metrics

38 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$19.23
Market cap
$897.43M

Price action

23 metrics
Price change (1W)
-4.8%
Price change (30D)
+4.4%
Price change (3M)
-12.4%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
71.9%
Annualized volatility (3M)
82.8%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.1
RSI (14D)
45.6
Price vs SMA 50
-11.4%
Price vs SMA 200
—
Avg volume (3M)
278,956
Relative volume
1.6
Average dollar volume
$6.09M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
48.07M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.4
reciprocal yield 41.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-04

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-211.05

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+953.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
12.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
12.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$326.00M
Latest balance sheet
Cash & equivalents
$80.64M
Total assets
$438.10M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
59
13F filer change QoQ
+59
Institutional ownership
72.6%
Conviction holders (share of 13F filers)
10.2%
Crowding (high-turnover and private-fund holders)
43.4%
Private-fund adviser ownership
43.3%
Active holders' share change QoQ
—
Holder tenure
1.0
Price vs estimated holder cost
+6.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.5%

Short interest

3 metrics
Short interest
6.8%
Latest settlement · 12.4 days to cover
Days to cover
12.4d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1882782 CUSIP 67613T104 13F (30d) 11 filings 11 filers Visit website Investor relations